Deep vein thrombosis, usually shortened to DVT, became a trending search term in October 2026 because a well-known American football player was diagnosed with it. Jalen Hurts, the quarterback of the Philadelphia Eagles, was found to have DVT together with blood clots in both lungs, a condition called bilateral pulmonary embolism, according to a team and agent statement reported by Time and NFL.com on 19 October 2026. A celebrity diagnosis on that scale pulls a medical term that most people rarely encounter into general news feeds within hours.
DVT means a blood clot forming in a deep vein, most often in the thigh or lower leg, where it can partly or fully block the flow of blood back to the heart. The serious danger appears when part of that clot breaks free and travels through the bloodstream to the lungs, which is what doctors call a pulmonary embolism, or PE. DVT and PE together are grouped under the umbrella term venous thromboembolism, abbreviated VTE, and they are treated as one connected disease rather than two separate problems.
The Hurts case followed a documented sequence that reporters were able to lay out from team statements and medical updates. A calf contusion on 4 October 2026 was followed by an ultrasound in London on 10 October that showed superficial vein thrombosis, and a later follow-up scan showed that the clot had moved, which led to injured reserve. Reports from ESPN and CBS Sports said he was expected to miss the rest of the season and to need at least three months of anticoagulation, the drug treatment that prevents clots from growing or recurring.
The statement issued through the team and his agent described Hurts as clinically stable, with no significant functional limitations, and gave a very good prognosis with full recovery expected. That wording matters because it distinguishes between the immediate medical situation and the longer recovery path that follows a clot in the lungs. Coverage in Time and on NFL.com presented the diagnosis as serious but treatable rather than as a career-ending event, which shaped how the public read the story.
Media coverage framed the case as the latest entry in a longer list of professional athletes who have been diagnosed with blood clots, an angle carried by the Associated Press. That framing pushed the public conversation toward a specific question: why does this happen to people who train daily and appear to be in peak physical condition. Fitness and youth reduce some risks but do not remove them, and the reporting did not claim that athletes are protected from clotting disorders.
The timing of the news amplified the attention it received. World Thrombosis Day fell on 13 October 2026, less than a week before the diagnosis was announced, and it is an annual awareness campaign run by the International Society on Thrombosis and Haemostasis, known as ISTH. The ISTH said its 2026 campaign reached 123 countries and focused on women's clot risk, while hospitals and health services ran their own awareness pushes around the same date. A public already primed to notice the phrase blood clots was therefore ready to search for it when the sports story broke.
The ISTH campaign highlighted pregnancy as a period of elevated clot risk, stating that pregnant women are roughly five times more likely to develop a blood clot, with the highest risk falling in the first six weeks after delivery. The same ISTH material noted that up to 60 per cent of VTE cases occur during or within 90 days of a hospital stay, which points to immobilisation and illness rather than lifestyle alone. These figures explain why awareness campaigns target expectant mothers, new mothers and recently hospitalised patients as distinct groups.
A large study published on 19 October 2026 in the Lancet Obstetrics, Gynaecology & Women's Health examined common painkillers in people who also use hormonal contraceptives. Among more than three million users across four European countries, the risk of venous thromboembolism was already rising before the anti-inflammatory drug was started and peaked on the day it began, with a similar pattern appearing for paracetamol. The authors suggested that the underlying illness driving people to take a painkiller may explain much of the association, rather than the drug acting alone, as reported by Medical Xpress.
The BOLT-DVT trial, presented on 3 and 4 October 2026 at The VEINS conference in Las Vegas, tested a mechanical approach to clearing clots. It was a prospective, multicentre study sponsored by Penumbra that enrolled 229 patients at 39 sites in the United States, with a mean age of 58 and 62 per cent women, all treated with computer-assisted vacuum thrombectomy as first-line therapy for acute iliofemoral DVT. According to Venous News, thrombus reduction of at least 75 per cent was achieved in 98 per cent of evaluable patients, and the 48-hour rate of major adverse events was 3.1 per cent.
The BOLT-DVT results carry important limits that any reader should weigh. It was a single-arm study without a randomised comparison group, it was sponsored by the device manufacturer, its primary endpoint was anatomical rather than a long-term patient outcome, and follow-up was short. Whether this kind of thrombectomy prevents post-thrombotic syndrome, a lasting complication of DVT, better than anticoagulation alone still has no randomised answer after the earlier ATTRACT and CAVA trials.
A separate audit reported on 17 October 2026 in Frontiers in Cardiovascular Medicine looked at where a clot sits and how that relates to lung complications. In one group of 160 patients, combined thrombosis in the muscular calf veins and the proximal veins was associated with a 57 per cent rate of pulmonary embolism. The finding supports the idea that location, not just the presence of a clot, should inform how closely a patient is monitored, though a single audit of this size cannot settle the question on its own.
Research also addressed the psychological side of the diagnosis. According to Bioengineer, 41 per cent of DVT patients screened positive for significant anxiety, and patients who received adequate counselling at the moment of diagnosis had roughly 58 per cent lower odds of that anxiety. The implication is practical rather than abstract: how a clinician explains the condition during the first conversation appears to shape how the patient copes in the following weeks. Anxiety does not change the clot itself, but it affects whether people adhere to treatment and follow-up.
The ADJUST-DVT study, published online in JAMA on 5 January 2026, tackled a different problem: how to rule DVT out without unnecessary imaging. Across 3,205 patients at 27 centres in Belgium, Canada, France and Switzerland, using an age-adjusted D-dimer cutoff of age multiplied by 10 micrograms per litre for patients aged 50 and over increased the proportion in whom DVT could be excluded by 7.4 percentage points. In patients aged 75 and older, the share with a negative D-dimer rose from 9 per cent to 26 per cent, with no false negatives at three months, as summarised by the American College of Cardiology.
Regulatory and guideline activity clustered in the same month. The United States Food and Drug Administration, known as the FDA, cleared the Hēlo thrombectomy system and the Hēlo Return blood return system from Endovascular Engineering, a 510(k) clearance announced in the week of 19 October 2026. Separately, the National Institute for Health and Care Excellence, or NICE, in the United Kingdom updated its guideline on venous thromboembolic diseases, including diagnosis, management and thrombophilia testing, on 10 October 2026.
For the first time, the Global Burden of Disease initiative produced global estimates of how many people develop these clots each year. The October 2026 figures reported by Thrombosis.org put new DVT cases at more than 2.5 million and new pulmonary embolisms at more than 1.6 million annually, a conservative reading of the data. The authors noted that VTE had historically been hidden inside vague categories in cause-of-death coding, which is why no reliable global number existed before.
Because PE is the complication that kills, the symptoms worth knowing are the ones that point to the lungs. Sudden shortness of breath, chest pain that worsens on a deep breath, a rapid heart rate, coughing up blood or fainting are warning signs that require emergency assessment rather than a wait-and-see approach. DVT itself often shows up as swelling in one leg, pain or tenderness in the calf or thigh, warmth, or skin that looks red or discoloured compared with the other leg.
Risk factors fall into a few broad groups that doctors consider together rather than one at a time. Immobility after surgery, a long flight or a period of bed rest slows blood flow; surgery, trauma and some cancers activate clotting; hormonal contraception, pregnancy and hormone therapy shift the balance further; and inherited clotting disorders, sometimes called thrombophilia, add a background risk that may only become visible when another factor appears. Age, smoking and obesity also raise the baseline. A calf contusion alone is a minor injury, but combined with travel and other factors it can contribute to a clot forming.
Anticoagulation remains the standard treatment, and the duration depends on what triggered the clot and whether the risk of bleeding outweighs the risk of another event. The reported plan for Hurts, at least three months of blood thinners, reflects a typical course for a provoked clot with a clear trigger, whereas unprovoked clots or those linked to cancer often lead to longer treatment. Patients are usually advised to avoid contact sports and activities with a high bleeding risk while on these drugs, which is why an athlete in season would step away from competition.
Prevention advice is mostly about movement and awareness rather than medication for the general population. On long journeys, getting up and walking at intervals, moving the ankles and calves while seated, and staying hydrated are commonly recommended, and compression stockings are sometimes suggested for people at higher risk. After surgery or during a hospital stay, clinicians may use mechanical compression or preventive doses of blood thinners, guided by an individual risk assessment. Anyone with a personal or family history of clots should raise it before surgery, long travel or starting hormonal treatment.
The October 2026 spike in searches had several reinforcing causes rather than one. A high-profile athlete's diagnosis of DVT with clots in both lungs on 19 October came days after World Thrombosis Day on 13 October and in the same period as new trial data, an updated NICE guideline, an FDA device clearance and the first global burden estimates, so news and awareness activity landed together. The episode also left a useful public takeaway: DVT is common, often treatable, and worth recognising early, because the difference between a managed clot and a pulmonary embolism depends heavily on how quickly it is found.
